No.4
適時開示 適時開示
2026/09/28 13:13
事業の状況
VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED ORPHAN DRUG DESIGNATION IN JAPAN
📄 開示資料(HKEXnews)を開く
削除
No.3
適時開示 適時開示
2026/09/23 22:47
中間報告書
2026 INTERIM REPORT
📄 開示資料(HKEXnews)を開く
削除
No.2
適時開示 適時開示
2026/09/21 23:12
事業の状況
VOLUNTARY ANNOUNCEMENT PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED EP-NEC SELECTED AS LBA AND THREE STUDIES SELECTED FOR PROFFERED PAPER PRESENTATIONS AT 2026 ESMO
📄 開示資料(HKEXnews)を開く
削除
No.1
適時開示 適時開示
2026/09/14 18:10
事業の状況
VOLUNTARY ANNOUNCEMENT UPDATED DATA FROM PHASE II CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR NSCLC PRESENTED ORALLY AT WCLC 2026
📄 開示資料(HKEXnews)を開く
削除